EWA
BHVN

EverSource Wealth Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

EverSource Wealth Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-254
Closed -$38K – 2477
2022
Q3 		$38K Sell
254
-26
-9% -$3.85K 0.01% 714
2022
Q2 		$41K Buy
280
+212
+312% +$27.1K 0.01% 674
2022
Q1 		$8K Hold
68
– – ﹤0.01% 1117
2021
Q4 		$9K Buy
+68
New +$8.65K ﹤0.01% 1032

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

EverSource Wealth Advisors's BHVN Position: Q4 2022 in Review

EverSource Wealth Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 254 shares — an estimated $38K sold.

EverSource Wealth Advisors first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $41K in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • EverSource Wealth Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • EverSource Wealth Advisors sold 254 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $38K.
  • EverSource Wealth Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • EverSource Wealth Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $41K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on EverSource Wealth Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.